Results 131 to 140 of about 20,750 (203)

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series. [PDF]

Front Endocrinol (Lausanne)
Yamin T, Cohen O, Robenshtok E, Izkhakov E, Miodovnik M, Gutfeld O, Leshem Y, Meirovitz R, Warshavsky A, Muhanna N, Finkel I.   +10 more
europepmc   +1 more source

Fatal tracheal perforation following Dabrafenib-Trametinib therapy in <i>BRAF</i> V600E-mutant mixed anaplastic thyroid cancer. [PDF]

JCEM Case Rep
Matrone A, Scordo M, Minaldi E, Torregrossa L, Materazzi G, Elisei R.   +5 more
europepmc   +1 more source

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i>^<i>V600E</i> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. [PDF]

JCO Precis Oncol
Salama AKS, Wang V, Macrae ER, Park JI, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.   +18 more
europepmc   +1 more source

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer? [PDF]

J Thorac Dis
Yonesaka K.
europepmc   +1 more source

PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models. [PDF]

J Exp Clin Cancer Res
Valentini E, Gentile G, Di Martile M, D'Aguanno S, Brignone M, Di Stefano AM, Di Caprio M, Melucci E, Botti C, Pelle F, Ortolano A, Fattore L, Mancini R, Ciliberto G, Rotili D, Del Bufalo D.   +15 more
europepmc   +1 more source

BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity. [PDF]

Eur Thyroid J
Riesco-Eizaguirre G.
europepmc   +1 more source

Successful Treatment of BRAF-Mutated Metastatic Melanoma in an Advanced-Age Patient with Dabrafenib and Trametinib: A Case Report and Literature Review. [PDF]

Case Rep Oncol
Kim CS, Kim JJ, Oh SB.
europepmc   +1 more source

EpCAM activates the ERK-EGR1 signaling axis and promotes TNF-α-induced the progression of anaplastic thyroid cancer. [PDF]

J Transl Med
Lee CC, Su YJ, Panda SS, Chiu CY, Wu CH, Lu TM, Li PC, Huang YL, Hong RL, Hung SH, Yee C, Lai SY, Wu HC.   +12 more
europepmc   +1 more source

Gyógyítható lesz-e a melanoma? Perspektívák a melanoma kezelésében = Will melanoma be curable? Perspectives in melanoma therapy [PDF]

, 2017
Baltás, Eszter, Gyulai, Rolland, Lengyel, Zsuzsanna   +2 more
core   +1 more source

Efficacy and safety of Dabrafenib in Erdheim-Chester disease. [PDF]

Ann Hematol
Liu ZZ, Liu WT, Miao HL, Chang L, Lang M, Lin H, Duan MH, Cao XX.   +7 more
europepmc   +1 more source